Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds were identified using a virtual screening approach.

Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approvalMature da ...

These healthcare REITs are rated Buy at Jefferies and make sense now for investors seeking dependable passive income and a ...

While sleep supplements can be beneficial, the lack of regulation means consumers are not assured of a safe and effective product.